Corcept Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Corcept Therapeutics Inc 公司

Corcept Therapeutics Incorporated 是一家商业阶段公司，致力于发现和开发通过调节激素皮质醇作用来治疗严重内分泌、肿瘤、代谢和神经系统疾病的药物。该公司通过发现、开发和商业化医药产品部门开展业务。该公司已在美国销售 Korlym（米非司酮），用于治疗患有库欣综合征的患者。该公司的选择性皮质醇调节剂产品组合由四个系列组成，共计约 1,000 种化合物。其选择性皮质醇调节剂产品组合包括 relacorilant、exicorilant、dazucorilant 和 miricorilant。Korlyms 的活性成分米非司酮可减少过量皮质醇与 GR 的结合，它可以调节皮质醇异常水平和释放模式的影响，而不会损害皮质醇的健康功能和节律。

Corcept Therapeutics Inc简介



公司代码CORT

公司名称Corcept Therapeutics Inc

上市日期Apr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

员工数量500

证券类型Ordinary Share

年结日Apr 15

公司地址101 Redwood Shores Parkway

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编94065

电话16506888803

网址https://www.corcept.com/

公司代码CORT

上市日期Apr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

Corcept Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

Mr. Atabak Mokari

Chief Financial Officer, Treasurer

14.32K

+1.82%

Mr. Joseph Douglas Lyon

Chief Accounting and Technology Officer

10.28K

--

Mr. William Guyer, Pharm.D.

Chief Development Officer

5.29K

--

Mr. Gregg Huber Alton, J.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 8月17日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.74%

The Vanguard Group, Inc.

9.17%

Ingalls & Snyder LLC (Asset Management)

7.33%

Renaissance Technologies LLC

5.95%

Baker (George Leonard Jr.)

5.04%

其他

61.78%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.74%

The Vanguard Group, Inc.

9.17%

Ingalls & Snyder LLC (Asset Management)

7.33%

Renaissance Technologies LLC

5.95%

Baker (George Leonard Jr.)

5.04%

其他

61.78%

股东类型

持股股东

占比

Investment Advisor

39.89%

Investment Advisor/Hedge Fund

23.01%

Individual Investor

11.62%

Hedge Fund

8.65%

Research Firm

1.60%

Pension Fund

1.21%

Sovereign Wealth Fund

0.96%

Bank and Trust

0.44%

Venture Capital

0.25%

其他

12.37%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

771

80.09M

76.01%

-11.97M

2025Q2

740

96.93M

91.97%

-8.00M

2025Q1

746

97.45M

92.10%

-9.12M

2024Q4

673

98.29M

93.20%

-10.89M

2024Q3

625

101.82M

97.42%

-10.51M

2024Q2

589

103.22M

99.09%

-12.69M

2024Q1

582

107.51M

103.94%

+2.98M

2023Q4

555

98.31M

95.40%

-4.22M

2023Q3

540

96.45M

94.14%

-5.68M

2023Q2

523

94.35M

92.83%

-12.18M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

11.31M

10.74%

-1.71M

-13.12%

Jun 30, 2025

The Vanguard Group, Inc.

9.66M

9.17%

-301.38K

-3.03%

Jun 30, 2025

Ingalls & Snyder LLC (Asset Management)

7.72M

7.33%

-19.66K

-0.25%

Jun 30, 2025

Renaissance Technologies LLC

6.27M

5.95%

+123.37K

+2.01%

Jun 30, 2025

Baker (George Leonard Jr.)

5.31M

5.04%

--

Apr 17, 2025

Parallel Advisors, LLC

3.87M

3.67%

-101.29K

-2.55%

Jun 30, 2025

Belanoff (Joseph K)

2.98M

2.83%

-615.00

-0.02%

Jul 17, 2025

State Street Global Advisors (US)

2.97M

2.82%

-434.35K

-12.77%

Jun 30, 2025

Wilson (James N)

2.35M

2.23%

+129.14K

+5.82%

Apr 17, 2025

Dimensional Fund Advisors, L.P.

2.09M

1.98%

-50.99K

-2.39%

Jun 30, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

Invesco S&P SmallCap Health Care ETF

4.45%

Formidable ETF

3.5%

SPDR S&P Pharmaceuticals ETF

3.21%

First Trust NYSE Arca Biotechnology Index Fund

3.15%

iShares U.S. Pharmaceuticals ETF

3.06%

Invesco S&P SmallCap Momentum ETF

2.53%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.34%

Invesco Pharmaceuticals ETF

2.16%

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.1%

Invesco S&P SmallCap 600 Pure Growth ETF

1.52%

Invesco S&P SmallCap Health Care ETF

占比4.45%

Formidable ETF

占比3.5%

SPDR S&P Pharmaceuticals ETF

占比3.21%

First Trust NYSE Arca Biotechnology Index Fund

占比3.15%

iShares U.S. Pharmaceuticals ETF

占比3.06%

Invesco S&P SmallCap Momentum ETF

占比2.53%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.34%

Invesco Pharmaceuticals ETF

占比2.16%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比2.1%

Invesco S&P SmallCap 600 Pure Growth ETF

占比1.52%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据